Abnormal phenotype of Nrf2 is associated with poor prognosis through hypoxic/VEGF-A-Rap1b/VEGFR2 pathway in gastric cancer

Ya Yang¹, Xin Wang¹, Jia Zhang², Hao Gu¹, Song Zhang¹, Hao Sun¹, Junqi Liu¹, Ruitai Fan¹

¹Department of Radiotherapy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan, China
²Department of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, Shaanxi, China

Correspondence to: Ruitai Fan; email: fanruitai@126.com, https://orcid.org/0000-0002-1371-8930
Keywords: gastric cancer, Nrf2, Rap1b, hypoxic, prognosis
Received: November 11, 2020  Accepted: November 11, 2021  Published: April 13, 2022

ABSTRACT

Metastasis is the major cause of death in gastric cancer patients and altered expression of Nrf2 is associated with cancer development. This study assessed Nrf2 and HO-1 expression and hypoxia-induced Nrf2 expression in the promotion of metastatic potential of gastric cancer cells, the relationship of Rap1b and Nrf2 was also discussed. Nrf2 and HO-1 expression were significantly associated with clinicopathological characteristic and were independent prognostic predictors in gastric cancer patients. Hypoxia up-regulated the expression of Nrf2, HO-1 and HIF-1α, whereas knockdown of Nrf2 inhibited cell invasion capacity and reduced the expression of Nrf2, HO-1 and HIF-1α. Patients in the Rap1b (+) Nrf2 (+) group had worst overall survival compared with those from other groups. Knockdown of Rap1b and Nrf2 significantly inhibited cell invasion capacity in the common group compared with the other groups. Hypoxia or VEGF-A facilitated the nuclear translocation of Nrf2 through Rap1b or VEGFR2. Hypoxia or VEGF-A did not induce the phosphorylation of P-Erk1/2 and P-Akt after knockdown of Rap1b or VEGFR2. Hypoxia promoted the gastric cancer malignant behavior through the upregulation of Rap1b and Nrf2. Hypoxia/VEGF-A-Rap1b/VEGFR2 facilitated the nuclear translocation of Nrf2. Targeting Rap1b and Nrf2 may be a novel therapeutic strategy for gastric cancer.

INTRODUCTION

Gastric cancer (GC) is one of the most important malignancies globally; it is the fifth most commonly diagnosed and the third major cause of cancer-related mortality [1]. In the previous decades, although the GC incidence rate was experiencing a steady decline globally, the median survival was less than 12 months for the advanced stage [2, 3]. Given that the early symptoms of GC are not obvious, GC is often diagnosed at an advanced stage and has a poor prognosis. Recent data indicates that the prevalence of GC is particularly high in Eastern Asian countries such as China, Japan, and Korea [4, 5]. Studies have documented that GC is a highly invasive heterogeneous malignant tumor. Gene mutations, epigenetic changes, and abnormal molecular signaling cascades participate in the development, diffusion, and metastasis of GC. Identification of the molecular profile of GC can provide milestone progress in achieving effective treatment and enhancing the quality of life, as well as reducing the mortality rates of GC patients.

Nrf2 is a member of the NF-E2 family of transcription factors with a basic leucine zipper. Kelch-like ECH-associated protein 1 (Keap1) acts as a cysteine-rich suppressor protein and docks to Nrf2. In normal conditions, Keap1 inhibits Nrf2 activity; however, under oxidative stress, Nrf2 dissociates from Keap1, promoting the activation of Nrf2. Nrf2 positively regulates anti-inflammatory, antioxidant, detoxification and drug resistance effects to protect normal cells from oxidative stress and exogenous stimuli [6]. In addition, Nrf2 participates in various cell activities, such as cancer cell
proliferation and invasion, apoptosis, chemoresistance, cell cycle repair, tissue regeneration, and immune regulation [7]. Nrf2 is overexpressed in a variety of tumor cells and has been correlated with the occurrence and progression of many tumors, including advanced lung cancer, squamous cell carcinoma of the head and neck, liver cancer, esophageal squamous cell cancer, colon cancer, pancreatic cancer, gastric cancer, and gallbladder cancer [8, 9]. Nrf2 may be a remarkable signature for the prognosis of individuals with GC and play an indispensable role in the onset and progress of GC.

The association between Nrf2 and GC has been reported in several studies, but the significance of Nrf2 in GC metastases and invasion is not well elucidated. Hence, we explored the relationship between Nrf2 and GC, as well as possible mechanisms and signaling pathways. Hypoxia is known to play an important role in the TME (tumor microenvironment) to impact tumor cell survival, as well as malignant behaviors [10, 11]. Therefore, we explored the relationship between hypoxia and Nrf2, as well as related mechanisms in the invasion of GC. Previous investigations found that Rap1b and hypoxia-inducible factor-1 alpha (HIF-1) protein expression contribute to the GC malignant behavior along with poor prognosis [12]. Nevertheless, the function of Rap1b and its crosstalk with Nrf2 in GC remains unclear.

RESULTS

The clinicopathological data of GC patients is related to the differential expression of the proteins Nrf2 and HO-1

In GC tissues, Nrf2 was mainly localized in the nucleus (Figure 1B) and concomitant cytoplasmic staining was partly observed. In para-cancer normal tissues, Nrf2 was primarily located in the cytoplasm and HO-1 was predominantly expressed in the cytoplasm (Figure 1C). In cancer tissues, the positive expression rate of Nrf2 was 73.59% (131/178), and the positive expression rate of HO-1 was 69.66% (124/178). Nrf2 along with HO-1 proteins expression was remarkably different between GC and neighboring non-malignant tissues (Nrf2, P<0.001; HO-1, P<0.001) (Table 1). Expression of Nrf2 protein was remarkably associated with the depth of infiltration (P<0.001), regional lymph nodes (P<0.001), distant metastasis (P<0.001), Borrmann type (P<0.001) along with TNM staging (P =0.014) but not with gender, age, tumor differentiation or tumor diameter (Table 2). Similar results were observed for HO-1. In addition, Nrf2 expression was positively related with the expression of HO-1 (r = 0.605, P<0.001) and HIF-1α (r =0.446, P<0.001) (previous studies [12]; Table 3).

Figure 1. Immunohistochemical expression of Nrf2 and heme oxygenase-1 (HO-1) in gastric cancer (GC) and para-carcinoma tissues. (A) Slides without primary antibody served as the negative control in GC tissues. (B) Typical immunohistologic features with Nrf2 expression in GC tissues. The Nrf2 staining localized predominantly in the nucleus. (C) Typical immunohistologic features with HO-1 expression in GC tissues. (D) Typical immunohistologic features with Nrf2 expression in para-carcinoma tissues. Magnifications, ×200.
Table 1. Differences in Nrf2 and HO-1 between the cancer tissues and para-carcinoma tissues.

| Group          | Nrf2  |     | P    | HO-1  |     | P    |
|----------------|-------|-----|------|-------|-----|------|
|                | +     | -   |       | +     | -   |      |
| cancer         | 131   | 47  | <0.001| 124   | 54  | <0.001|
| para-carcinoma | 30    | 148 |       | 65    | 113 | <0.001|
| total          | 161   | 195 |       | 189   | 167 |      |

Table 2. Correlations between the clinicopathologic variables with Nrf2 and HO-1.

| Variables          | N  | Nrf2  |     | P    | HO-1  |     | P    |
|--------------------|----|-------|-----|------|-------|-----|------|
|                    |    | High  | Low |      | High  | Low |      |
| Gender             |    |       |     |      |       |     |      |
| Male               | 125| 82    | 43  | 0.397| 73    | 52  | 0.824|
| Female             | 53 | 31    | 22  |       | 30    | 23  |      |
| Age                |    |       |     |      |       |     |      |
| ≤ 60               | 94 | 58    | 36  | 0.602| 53    | 41  | 0.672|
| > 60               | 84 | 55    | 29  |       | 50    | 34  |      |
| TNM                |    |       |     |      |       |     |      |
| I                  | 21 | 9     | 12  |       | 9     | 12  |      |
| II                 | 34 | 20    | 14  |       | 15    | 19  |      |
| III                | 83 | 52    | 31  |       | 51    | 32  |      |
| IV                 | 40 | 32    | 8   | <0.001| 28    | 12  | <0.001|
| Depth of invasion  |    |       |     |      |       |     |      |
| T1                 | 16 | 4     | 12  |       | 6     | 10  |      |
| T2                 | 18 | 12    | 6   |       | 7     | 11  |      |
| T3                 | 67 | 48    | 19  |       | 43    | 24  |      |
| T4                 | 77 | 49    | 28  | <0.001| 47    | 30  | <0.001|
| Nodal involvement  |    |       |     |      |       |     |      |
| N0                 | 49 | 26    | 23  |       | 22    | 27  |      |
| N1                 | 36 | 18    | 18  |       | 18    | 18  |      |
| N2                 | 35 | 22    | 13  |       | 22    | 13  |      |
| N3                 | 58 | 47    | 11  | <0.001| 41    | 17  | <0.001|
| Metastasis         |    |       |     |      |       |     |      |
| M0                 | 138| 81    | 57  | 0.014| 73    | 65  |      |
| M1                 | 40 | 32    | 8   |       | 30    | 10  | 0.013|
| Borrmann type      |    |       |     |      |       |     |      |
| I                  | 22 | 12    | 10  |       | 10    | 12  |      |
| II                 | 55 | 31    | 24  |       | 31    | 24  |      |
| III                | 62 | 44    | 18  |       | 39    | 23  |      |
| IV                 | 39 | 26    | 13  | <0.001| 23    | 16  | <0.001|
| Differentiation    |    |       |     |      |       |     |      |
| High               | 12 | 7     | 5   |       | 5     | 7   |      |
| Moderate           | 57 | 34    | 23  |       | 31    | 26  |      |
| Poor               | 109| 72    | 37  | 0.667| 67    | 42  | 0.340|
| Tumor diameter     |    |       |     |      |       |     |      |
| <3cm               | 44 | 22    | 22  |       | 20    | 24  |      |
| 3cm-5cm            | 54 | 38    | 16  |       | 33    | 21  |      |
| >5cm               | 80 | 53    | 27  | 0.090| 50    | 30  | 0.156|
Table 3. Association between Nrf2 with HO-1 and HIF-1α.

|       | Nrf2               | HO-1 | HIF-1α | r     | P      |
|-------|---------------------|------|--------|-------|--------|
|       | High                | Low  |        |       |        |
| High  | 91                  | 22   |        | 0.605 | < 0.001|
| Low   | 12                  | 53   |        |       |        |
| High  | 80                  | 33   |        | 0.446 | < 0.001|
| Low   | 16                  | 49   |        |       |        |

Association of Nrf2 and HO-1 expression with patient survival

The results of the Kaplan-Meier curve and log-rank test exhibited a significant difference in overall survival (OS) between patients with high Nrf2 expression and those with low Nrf2 expression (Figure 2A and Table 4), 30 months (95% CI, 27.52-32.48) vs. 52 months (95% CI, 42.97-61.02, P<0.001), respectively. Similar results were observed for HO-1 expression (P<0.001, Figure 2B and Table 4). In addition, the multivariate Cox data illustrated that overexpression of Nrf2 (P = 0.035, RR = 1.583, 95% CI 1.033-2.426) and HO-1 (P<0.001, RR = 2.156, 95% CI 1.428-3.257) were independent predictive factors for the survival of individuals with GC (Table 5).

Nrf2 and HO-1 are upregulated in GC cells under hypoxic conditions

Previous studies confirmed that hypoxia could induce GC cell infiltration and increase HIF-1α expression at the protein level [12]. To verify whether hypoxia increases Nrf2 along with HO-1 expression and induces the invasion of GC cell, MKN28, BGC823 as well as SGC7901 cells were treated with 150 or 200 μM CoCl2 for 24 h. Our findings indicated an increase in Nrf2 and HO-1 mRNA and protein expression (Table 6 and Figures 3A, 4A, P<0.05). HIF-1α was upregulated at the mRNA level (Table 6 and Figure 3A, P<0.05). Therefore, hypoxia can increase the expression of Nrf2, HO-1, and HIF-1α in GC cells.

Silencing the expression of Nrf2 inhibits the invasion of GC cells under hypoxic conditions

To clarify the function of Nrf2 in GC cells, we found that siNrf2-1498 was the most effective sequence (Table 7 and Figure 3B). Therefore, we used a negative control and siNrf2-1498 to transfect GC cells, processed the cells with 150 or 200 μM CoCl2 for 24 h, and then conducted the transwell invasion experiment. Under hypoxic conditions, the invasive potential of MKN28, BGC823, as well as SGC7901 cell transfects of siNrf2-1498 was reduced remarkably (P<0.05, Figure 5).

Figure 2. Kaplan-Meier survival analysis of Nrf2, HO-1 and Rap1b expression levels. (A) Differences in the cumulative OS among patients with Nrf2 protein expression. (B) Differences in the cumulative OS among patients with HO-1 protein expression. (C) Differences in cumulative OS among patients with Nrf2 and Rap1b protein expression. The P-value was obtained using the log-rank test of the difference. (**P<0.001).
Table 4. Univariate analysis for overall survival.

| Variables         | N   | Overall survival |          |          |          |          |          |          |
|-------------------|-----|------------------|----------|----------|----------|----------|----------|----------|
|                   |     | Median±SE        | 95%CI    |          |          |          |          |          |
| Nrf2              |     |                  |          |          |          |          |          |          |
| High              | 113 | 30.00 ± 1.26     | 27.52–32.48 |          |          |          |          |          |
| Low               | 65  | 52.00 ± 4.60     | 42.97–61.02 | < 0.001  |          |          |          |          |
| HO-1              |     |                  |          |          |          |          |          |          |
| High              | 103 | 29.00 ± 1.56     | 25.94–32.06 |          |          |          |          |          |
| Low               | 75  | 52.00 ± 5.77     | 40.68–63.31 | <0.001   |          |          |          |          |
| Gender            |     |                  |          |          |          |          |          |          |
| Male              | 125 | 34.00±2.97       | 28.16–39.83 |          |          |          |          |          |
| female            | 53  | 38.00±3.63       | 30.86–45.13 | 0.973    |          |          |          |          |
| Age               |     |                  |          |          |          |          |          |          |
| ≤60               | 94  | 40.00±3.87       | 32.40–47.59 |          |          |          |          |          |
| >60               | 84  | 32.00±1.13       | 29.77–34.22 | 0.223    |          |          |          |          |
| TNM               |     |                  |          |          |          |          |          |          |
| I                 | 21  | 49.00±3.21       | 42.69–66.71 |          |          |          |          |          |
| II                | 34  | 45.00±5.83       | 33.57–56.42 |          |          |          |          |          |
| III               | 83  | 34.00±2.27       | 29.53–38.46 |          |          |          |          |          |
| IV                | 40  | 29.00±1.57       | 25.91–32.08 | <0.001   |          |          |          |          |
| Depth of invasion |     |                  |          |          |          |          |          |          |
| T1                | 16  | 46.00±8.66       | 29.01–62.98 |          |          |          |          |          |
| T2                | 18  | 52.00±15.91      | 20.81–83.18 |          |          |          |          |          |
| T3                | 67  | 35.00±4.60       | 25.98–44.01 |          |          |          |          |          |
| T4                | 77  | 31.00±1.45       | 28.14–33.86 | 0.005    |          |          |          |          |
| Nodal involvement |     |                  |          |          |          |          |          |          |
| N0                | 49  | 55.00±9.79       | 35.79–74.20 |          |          |          |          |          |
| N1                | 36  | 43.00±7.80       | 27.22–58.78 |          |          |          |          |          |
| N2                | 35  | 36.00±3.54       | 29.04–42.95 |          |          |          |          |          |
| N3                | 58  | 29.00±2.53       | 24.03–33.96 | <0.001   |          |          |          |          |
| Metastasis        |     |                  |          |          |          |          |          |          |
| M0                | 138 | 40.00±3.91       | 32.32–47.67 |          |          |          |          |          |
| M1                | 40  | 29.00±1.57       | 25.91–32.08 | <0.001   |          |          |          |          |
| Borrmann type     |     |                  |          |          |          |          |          |          |
| I                 | 22  | 39.00±7.62       | 24.06–53.93 |          |          |          |          |          |
| II                | 55  | 40.00±3.69       | 32.76–47.23 |          |          |          |          |          |
| III               | 62  | 34.00±3.50       | 27.14–40.85 |          |          |          |          |          |
| IV                | 39  | 30.00±1.77       | 27.51–34.48 | 0.502    |          |          |          |          |
| Differentiation   |     |                  |          |          |          |          |          |          |
| high              | 12  | 40.00±6.06       | 28.11–51.88 |          |          |          |          |          |
| moderate          | 57  | 39.00±6.11       | 26.97–51.02 |          |          |          |          |          |
| poor              | 109 | 32.00±1.74       | 28.59–35.41 | 0.107    |          |          |          |          |
| Tumor diameter    |     |                  |          |          |          |          |          |          |
| <3cm              | 44  | 46.00±5.20       | 35.79–56.20 |          |          |          |          |          |
| 3cm-5cm           | 54  | 34.00±1.83       | 30.40–37.51 |          |          |          |          |          |
| >5cm              | 80  | 32.00±0.98       | 30.06–33.93 | 0.019    |          |          |          |          |

Table 5. Multivariate Cox proportional hazards analysis for overall survival.

| Variables         | RR  | 95% CI         |          |          |          |          |          |          |
|-------------------|-----|----------------|----------|----------|----------|----------|----------|----------|
| Overall survival  |     |                |          |          |          |          |          |          |
| TNM               | 1.615 | 1.309–1.994 | < 0.001 |          |          |          |          |          |
| HO-1              | 2.156 | 1.428–3.257 | < 0.001 |          |          |          |          |          |
| Nrf2              | 1.583 | 1.033–2.426 | 0.035   |          |          |          |          |          |
Table 6. The primer sequences.

| Primer | Sequence |
|--------|----------|
| Nrf2   | 5’ TCAGCGACGGAAAGAGTA TGA 3’, 5’ CCACTGTTTCTGACTGGATG T 3’ |
| HO-1   | 5’ CAGGCAGAGAATGCTGAGTTC 3’, 5’ CCACTGGTTTCTGACTGGATG T 3’ |
| HIF-α  | 5’ CATCACCAGCTTAAAGCCTT 3’, 5’ GAAACGTCGAAAAGAAAAGTCTCG 3’ |
| VEGFR2 | 5’ TCCGTTTCCTGCAGTCTCCGCA 3’, 5’ AGAGGCCAGCCTGCTGACGTCAT 3’ |
| VEGF-A | 5’ CACCGGCTCGGCTTGTCACAT 3’, 5’ CTGCTGTCTTGGGTGCATCTG 3’ |
| GAPDH  | 5’ CTGGGGCTCATTTG 3’, 5’ CATCCACAGTCTTC 3’ |

Silencing of Nrf2 expression repressed HO-1 and HIF-1α expression in hypoxic conditions (P<0.05, Figures 3C, 4B). Therefore, Nrf2 facilitates the infiltration potential of GC cells in a hypoxic environment.

**Relationship between Rap1b and Nrf2**

Rap1b and Nrf2 can promote the invasion and metastasis of GC. Whether the two have a synergistic effect on the progression of GC remains unclear. To confirm the correlation between Rap1b and Nrf2, Spearman’s analysis showed that the two were positively correlated (r = 0.581, P<0.001, Table 8). Univariate survival assessment exhibited that in contrast with patients from other groups, patients in the Nrf2 (+) Rap1b (+) group had the worst survival (OS 26.58 ± 1.30, 95% CI 24.02-29.14) (Table 9 and Figure 2C). Rap1b and Nrf2 can be used as joint markers to assess the prognosis of GC patients. Furthermore, the silencing of Rap1b and Nrf2 remarkably repressed the tumor cell infiltration capacity in the common group in contrast with the other groups, especially in the negative control group (Figure 6).

**Nuclear translocation of Nrf2**

We further verified the possible regulatory relationship between Rap1b and Nrf2 and the impact of hypoxia on the nuclear translocation of Nrf2 in BGC823 cells under normoxia. Nrf2 was found to be located in the cytoplasm under normoxia (Figure 7A) and in the nucleus under hypoxia (Figure 7B). VEGF-A enhanced nuclear translocation of Nrf2 (Figure 7C). In the negative control group under hypoxia conditions, Nrf2 was located in the nucleus (Figure 8A); however, in the siRap1b (Figure 8B) and siVEGFR2 (Tables 6, 7 and Figures 9A, 8C) groups, there was no Nrf2 entering the nucleus. Under normoxic conditions, silencing Rap1b and VEGFR2, VEGF-A was used to stimulate BGC823 but Nrf2 did not shift to the nucleus (Figure 8D, 8E). This suggested that Rap1b and VEGFR2 could participate in Nrf2’s nuclear translocation. In addition, after siRap1b and siVEGFR2 were silenced, the expression of P-Erk1/2 (Thr202/Thr204) and P-Akt (Thr308) was decreased under hypoxia and VEGF-A induction conditions (Figure 9C). Erk1/2 inhibitor (PD98059) and Akt inhibitor (LY294002) suppressed the nuclear translocation of Nrf2 by VEGF-A (Figure 10). Furthermore, hypoxia promoted the expression of VEGF-A in GC cells (Table 6 and Figure 9B). These results revealed that the hypoxia/VEGF-A-Rap1b/VEGFR2 pathway aided in Nrf2 nuclear translocation and that Erk and Akt signaling cascades were also implicated in Nrf2 nuclear translocation (Figure 11).

**DISCUSSION**

Nrf2 is a member of the NF-E2 family and a transcription factor with a basic leucine zipper. Nrf2 participates in the onset and progress of numerous tumors [7]. Herein, Nrf2 was mainly expressed in the nucleus in the GC tissue and was remarkably related with similar clinicopathological characteristics. This reveals that the high expression of Nrf2 promotes the progression of GC; the overexpression of Nrf2 was an independent predictive factor for the survival of GC patients.

These studies suggested that Nrf2 was related to the aggressive behavior of the GC.
Figure 3. Relative expression of mRNA. (A) Expression of Nrf2, HO-1 and HIF-1α in GC cells cultured under a hypoxic condition. (B) Expression of Nrf2 in GC cells after they were transfected with negative control siRNA or Nrf2 siRNAs (siNrf2-1498, siNrf2-2081 and siNrf2-2226). (C) Expression of Nrf2, HO-1 and HIF-1α in GC cells after they were transfected with siNrf2-1498 and cultured under a hypoxic condition. (*P<0.05, **P<0.001).
Figure 4. Protein expression under different conditions (A) Expression of Nrf2 and HO-1 in GC cells cultured under a hypoxic condition. The graphs show the quantified data of western blots. (B) Expression of Nrf2, HO-1 and HIF-1α in GC cells after they were transfected with siRNAs and cultured under a hypoxic condition. The graphs show the quantified data of western blot. (*P<0.05, **P<0.001).
Table 7. The small interference RNA sequences of human Nrf2 and VEGFR2.

| Gene           | Sequence                                      |
|----------------|-----------------------------------------------|
| Nrf2-homo-2081 | 5’ GCUGCUCAAGAAUUGCAGAATT 3’                  |
|                | 5’ UUCUGCAAUUCUGAGCGCTT 3’                   |
| Nrf2-homo-1498 | 5’ GCCAUUGAUGUUCUGAATT 3’                    |
|                | 5’ AUCAGAAACAUCAAUGGCTT 3’                   |
| Nrf2-homo-222  | 5’ GCACCUUAUAUCUGAAGUTT 3’                   |
|                | 5’ ACUUCGAUAUAAGGUGCTT 3’                   |
| Negative control siRNA | 5’ UUCUCGAAACGUGACCGUATT 3’             |
| VEGFR2-homo-366 | 5’ GGGUUUGCCAUAGUGUUUCUTT 3’                |
| VEGFR2-homo-633 | 5’ AGAAACACUGGCAAATCT 3’                    |
| VEGFR2-homo-990 | 5’ CUCGGUCAUUAUGCUGAATT 3’                  |
|                | 5’ AUAGACAAUAUGACCGAGTT 3’                  |
|                | 5’ GUCAUUGGAUUUGAUATT 3’                    |
|                | 5’ UAGUUCAUAUCCAGAGCTT 3’                   |

HO-1 was predominantly expressed in the cytoplasm, and exhibited similar results to Nrf2 with regards to clinico-pathological characteristics. HO-1 was positively correlated with Nrf2’s expression and can be used as a predictive factor for GC. High expression of Nrf2 along with HO-1 were also related to worse OS outcomes, with the capacity of serving as predictive signatures for prognosis of clear cell renal cell

Figure 5. Effects of Nrf2 knockdown on the regulation of the GC invasion capacity under a hypoxic condition. The invasion capacity was suppressed in GC cells transfected with siNrf2-1498 under hypoxic conditions. (A) MKN28 cells; (B) BGC823 cells; (C) SGC7901 cells; (D) The graph shows the quantified data of the assay. (**P<0.001).
Table 8. Association between Nrf2 and Rap1b.

|             | Rap1b |     |     |     |
|-------------|-------|-----|-----|-----|
|             | High  | Low |     |     |
| Nrf2        |       |     |     |     |
| high        | 87    | 26  |     |     |
| low         | 11    | 54  |     |     |
|             | r     |     |     |     |
|             | 0.581 |     |     |     |
|             | < 0.001 |     |     |     |

Table 9. Univariate analysis for overall survival.

| Variables         | N  | Overall survival |     |     |     |
|-------------------|----|------------------|-----|-----|-----|
|                   |    | Median±SE        | 95%CI|     |     |
| Nrf2(+), Rap1b(+) | 72 | 26.58±1.30       | 24.02–29.14 |     |     |
| Nrf2(+), Rap1b(-) | 40 | 44.37±2.36       | 39.74–49.00 | < 0.001 |
| Nrf2(-), Rap1b(+) | 26 | 43.96±2.59       | 38.88–49.04 |     |     |
| Nrf2(-), Rap1b(-) | 40 | 50.90±2.01       | 46.94–54.85 |     |     |

Figure 6. Effects of Nrf2 or (and) Rap1b knockdown on the regulation of the GC invasion capacity under a hypoxic condition.

The invasion capacity was suppressed in GC cells transfected with siNrf2RNA-1498 or (and) siRap1bRNA-501 under hypoxic conditions. (A) Negative control; (B) siRap1bRNA; (C) siNrf2RNA; (D) siRap1bRNA and siNrf2RNA; (E) The graph shows the quantified data of the assay. (*P<0.05, **P<0.001).
carcinoma patients [19]. Osteopontin-activated Nrf2 signaling enhanced HO-1 expression and migration of glioma cells [20]. Oxysophocarpine (OSC) weakened the expression of Nrf2, as well as HO-1 in oral squamous cell carcinoma (OSCC) cells. In addition, OSC suppressed the growth, migration, infiltration, as well as OSCC cells’ pro-angiogenesis. Furthermore, OSC attenuated the aggressive feature of OSCC cells via Nrf2/HO-1 signaling cascade inactivation [21]. A previous study revealed that ethanol mediated both the activation of Nrf2 and HO-1 to maintain colon cancer cell survival through matrix metallopeptidase 2 (MMP2), MMP9 and VEGF, thus leading to a more aggressive phenotype [22]. Low GRIM-19 (gene linked to retinoid-IFN- triggered mortality 19) is related to dismal survival outcome of individuals with GC. The deficiency of GRIM-19 enhances the metastasis of GC via the oncogenic ROS-Nrf2-HO-1 cascade through a positive-feedback Nrf2-HO-1 loop [23]. Herein, hypoxia up-regulated Nrf2 along with HO-1 expression in GC cells, whilst silencing of Nrf2 expression via siRNA repressed the invasion capacity of tumor cell even in hypoxic culture conditions and repressed Nrf2 expression along with HO-1, in vitro. Therefore, Nrf2/HO-1 signal cascade facilitates the GC invasion and metastasis.

Figure 7. Subcellular localization of Nrf2 in GC cells. (A) Normoxia (B) Hypoxia (C) VEGF-A (x1000).
Figure 8. Subcellular localization of Nrf2 in GC cells. (A) Hypoxia and negative control. (B) Hypoxia and siRap1b. (C) Hypoxia and siVEGFR2. (D) siRap1b and VEGF-A. (E) siVEGFR2 and VEGF-A (×400).
This study found that the HIF-1α expression was positively linked to Nrf2 expression. Under hypoxic conditions, silencing Nrf2 expression inhibited HIF-1α expression. Our previous study found that in esophageal squamous cell carcinoma cells, silencing Nrf2 expression could inhibit HIF-1α expression and reduce cell invasion under hypoxic conditions [18]. In breast cancer cells, it was shown that the overexpression of Nrf2 augments the expression of Notch1 via G6PD/HIF-1α pathway [24]. The lung cancer mouse model in the chronic intermittent hypoxia (CIH) group enhanced the β-catenin and Nrf2 nuclear translocation and activated subsequent effectors of Wnt/β-catenin signaling. CIH also did not trigger the expression of HIF-1α but induced the expression of VEGF. CIH facilitated proliferative along with migratory features of tumors in a mouse model of lung cancer [25]. Taken together, these findings suggest that HIF-1α can be regulated by Nrf2 through different mechanisms under hypoxic and intermittent hypoxic conditions. Nrf2 may affect the TME, making tumor cells more susceptible to invasion and metastasis. Therefore, future studies should highlight the dual functions of the Nrf2-Keap1 cascade in cancer enhancement and repression and

**Figure 9.** Relative expression of mRNA and the phosphorylation of protein (A) Expression of VEGFR2 in GC cells after they were transfected with negative control siRNA or VEGFR2 siRNAs (siVEGFR2-366, siVEGFR2-633 and siVEGFR2-990). (B) Expression of VEGF-A in GC cells cultured under a hypoxic condition. (C) Expression of Erk, P-Erk, Akt and P-Akt in GC cells after transfected with siRap1b or siVEGFR2 (left) Hypoxia (right) VEGF-A. (*P<0.05, **P<0.001).
describe the mechanisms of its activation, as well as possible treatment approaches based on the context-specific modulation of Nrf2 [7]. In these processes, Nrf2 facilitates the expression of invasion- and migration-related proteins, which reveals that Nrf2 functions as a molecular switch.

Hypoxia is a frequent microenvironment of solid tumors and is considered a powerful driving force, which affects every stage in the process of distant metastasis. Hypoxia and HIF-1α forward tumor migration along with infiltration and distant metastasis via different signaling cascades. The present premise found that under hypoxic conditions, silencing Rap1b or Nrf2 inhibited the invasion of GC cells and co-silencing remarkably inhibited cell invasion, and GC patients in the Nrf2 (+) Rap1b (+) group had the worst prognosis. This suggests that the two may have a synergistic effect. In addition, hypoxic conditions enhanced Nrf2’s nuclear translocation and knockdown of Rap1b inhibited the nuclear translocation of Nrf2. Vascular endothelial growth factor-A (VEGF-A) also accelerated the nuclear translocation of Nrf2 similar to hypoxic. Therefore, hypoxia or VEGF-A may facilitate the nuclear translocation of Nrf2 through Rap1b. In the astrocyte injury model, 2,7,2’-trihydroxy-4,4’7’-trimethoxy-1,1’-biphenanthrene (TTB) potentially activated the Nrf2/HO-1 cascade and protected against oxidative stress in oxygen-glucose deprivation/reoxygenation (OGD/R)-induced astrocytes by stimulating the nuclear translocation, as well as up-regulation of Nrf2 coupled with increased HO-1 expression. Treatment with TTB weakened the aggregation of HIF-1α and VEGF expressions triggered by OGD/R. TTB inhibited HIF-1α along with VEGF through the Nrf2/HO-1 signaling cascade and restrained OGD/R-triggered astrocyte oxidative stress [26]. CIH promoted β-catenin and Nrf2 nuclear translocation and activated subsequent effectors of Wnt/β-catenin signaling. Besides, CIH did not trigger the expression of HIF-1α but induced the expression of VEGF [25].

Several reports have confirmed that Rap1 regulates the activation of B-Raf/Erk/MAPK [27]. Rottlerin up-regulated Rap1 and the subsequent PI3K/Akt cascade independent of the MAPK/Erk cascade in a dexamethasone-triggered primary open-angle glaucoma cell model [28]. miR-518b promoted trophoblast cell growth via the Rap1b-Ras-MAPK cascade [29]. Adenosine produced by CD73 docked to adenosine A2A receptor-activated Rap1 and promoted Akt phosphorylation in hepatocellular carcinoma cells [30].

Figure 10. Subcellular localization of Nrf2 in GC cells. (A) PD98059 and VEGF-A (B) LY294002 and VEGF-A (x400).
Our results showed that knockdown of Rap1b, hypoxia or VEGF-A inhibited the phosphorylation of P-Erk1/2 (Thr202/Thr204) and P-Akt (Thr308). Erk1/2 inhibitor (PD98059) and Akt inhibitor (LY294002) suppressed the nuclear translocation of Nrf2 by VEGF-A. In leukemia cells, combined treatment of AZD0364 (ERK1/2 inhibitor) and ZSTK474 (PI3K inhibitor) reduced nuclear factor-κB and antioxidant protein levels (Nrf2, HO-1, thioredoxin reductase and the reduced glutathione/oxidized glutathione ratio) [31]. Antitumor activity of trastuzumab was enhanced when combined with brusatol in HER2-positive breast cancer cells, which was attributed to the inhibition of the Nrf2/HO-1 and HER2-Akt/Erk1/2 signaling cascades [32]. Cytosolic branched-chain aminotransferase enhances the growth, migration along with the infiltration of triple-negative breast cancer cells through the IGF-1/insulin PI3K/Akt cascade, culminating in the up-regulation of FOXO3a and Nrf2, indicating a novel therapeutic target for breast cancer treatment [33]. These data suggest that the hypoxic/VEGF-A-Rap1b/VEGFR2 cascade facilitates nuclear translocation of Nrf2, Erk, and Akt signal pathways participate in Nrf2’s nuclear translocation.

The activity of VEGFR2 promoted tumorigenicity and indicated poor survival in GC [34]. VEGF/VEGFR2 cascade is the central treatment target of the anti-angiogenic treatment for numerous cancers. Hypoxia enhanced Nrf2’s nuclear translocation and the knockdown of VEGFR2 inhibited the nuclear translocation of Nrf2. VEGF-A also enhanced Nrf2’s nuclear translocation similar to hypoxia. Besides, knockdown of VEGFR2, hypoxia or VEGF-A inhibited the phosphorylation of P-Erk1/2 and P-Akt (Thr308). Hypoxia or VEGF-A facilitates the nuclear translocation of Nrf2 through VEGFR2. Apatinib, an inhibitor of targeting VEGFR2, has been approved for third-line treatment of advanced GC [35]. Ramucirumab, the human immunoglobulin G1 monoclonal antibody receptor antagonist of VEGFR2, has been approved for the treatment of gastric/gastroesophageal junction

Figure 11. The scheme of hypoxic/VEGF-A-Rap1b/VEGFR2 pathway.
and non-small-cell lung and metastatic colorectal cancers [36]. However, these two drugs are used as a posterior-line treatment of GC; there are still numerous challenges in the treatment of GC via inhibiting VEGFR2.

In conclusion, our findings highlight the expression profile of Rap1b and Nrf2 in malignant behavior and poor prognosis. Hypoxic conditions promoted the aggressive behavior of GC cells through the up-regulation of Rap1b and Nrf2. Hypoxic/VEGF-A-Rap1b/VEGFR2 pathway facilitated the nuclear translocation of Nrf2. Targeting Rap1b and Nrf2 expression may be promising prognostic biomarkers, as well as novel therapeutic strategies in GC.

MATERIALS AND METHODS

Materials

Diaminobenzidine (DAB) was provided by Golden Bridge International (Beijing, China) and DMEM was provided by Life Technologies (Grand Island, NY, USA). FBS, Lipofectamine 2000 along with TRizol reagent were acquired from Invitrogen (Carlsbad, CA, USA). The Superscript II reverse transcriptase kit was supplied by Takara Bio Inc. (Otsu, Japan), as well as the ECL reagent along with PVDF membranes were commercially acquired from Merck Millipore (Darmstadt, Germany). The RIPA lysis buffer kit was acquired from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and the protein assay kit was obtained from Bio-Rad (Hercules, CA, USA). The membrane infiltration culture system was purchased from Corning (Corning, NY, USA). CoCl2 coupled with other reagents were supplied by Sigma (St. Louis, MO, USA).

Tissue specimens

Tissue specimens were taken from consecutive surgical cases of 178 GC patients in the Department of Surgical Oncology, the First Affiliated Hospital, School of Medical, Xi’an Jiaotong University and the Department of Surgical Oncology, the 215th Hospital of Shaanxi province, between 2004 and 2009. There are 125 male and 53 female patients, aged between 25 and 81 years old. The clinicopathological data from these patients are shown in Table 2. There were 77 patients (43.25%) whose tumors penetrated series or involved adjacent structures, 129 subjects (72.47%) exhibited lymph node metastases and 40 subjects (22.47%) harbored distant metastasis. 26 subjects were treated with total gastrectomy, whilst the remaining 152 subjects were treated with partial resection of tumor lesions. None of the 178 subjects received any neoadjuvant prior to surgery. However, there were 108 of 178 subjects receiving fluorouracil-based postoperative adjuvant chemotherapy. This study was approved by the Ethnic Committee of the First Affiliated Hospital, School of Medicine, Xi’an Jiaotong University.

Immunohistochemistry

The tissue sections were deparaaffinized and rehydrated, before antigen retrieval in a citrate buffer (pH 6.0) in the microwave. After that, we probed the sections with a goat polyclonal antibody against Nrf2 (1:600 Santa Cruz, CA, USA) or HO-1 (1:600 Biosynthesis Biotechnology, Beijing, China) overnight at 4°C. The secondary antibodies (SP-9001 along with PV-9003; Golden Bridge Intl., Beijing, China) were utilized to enlarge the signal. Visualization of the sections was done with 0.02% DAB solution to generate the positive color reaction, and counterstained with hematoxylin.

Cell lines and culture

MKN28, SGC7901 along with BGC823 human cell lines were supplied by Cell Bank of Shanghai (Shanghai, China) and maintained in DMEM containing high glucose and enriched with 10% FBS inactivated with heat. The cells at the logarithmic phase were used in the experiments.

Transwell invasion assay

Briefly, re-suspension of GC cell transfects of the control or sinNrf2 (3-5 × 104/well) was done in of serum-free DMEM (200 μL) enriched with CoCl2 (150 or 200 μM). The resuspension was subsequently introduced to the upper transwell chambers. In addition, we introduced DMEM (600 μL) enriched with FBS (20% (v/v)) along with CoCl2 (150 or 200 μM) to the lower transwell compartments to serve as a chemical attractant. The assays were run under 37°C and 5% CO2 for 24 hours. Afterwards, a cotton swap was utilized to remove the top cells, and fixation of the tumor cells which infiltrated the lower surface done with 4% PFA, followed by staining (in 1% crystal purple). For each insert, we selected 5 random fields for visualization with a light microscope. Each experiment was implemented in triplicate and repeated once.

siRNA and transfection

GenePharma Co. (Shanghai, China) devised and synthesized the small interference RNA molecules targeting human Nrf2 and VEGFR2. The following were the targeted sequences:
The GC cells were cultured and inserted with the negative control or Nrf2 siRNAs (VEGFR2 siRNAs) via a Lipofectamine 2000 in the light of the instructions of the manufacturer.

### RNA isolation and qRT-PCR

Purification of total cellular RNA from GC cells was done with the TRIzol reagent. After that, cDNA was generated from the RNA with the Superscript II Reverse Transcriptase kit as described by the manufacturer. qPCR was done using the primers:

The amplification conditions were 95°C for 30 s and 30 cycles of 95°C for 5 s, 60°C for 30 s and 72°C for 60 s for 30 cycles. The quantity of each transcript was standardized to that of GAPDH.

### Protein extraction and western blot

Lysis of cells was done in cold RIPA lysis buffer, and proteins quantitated with the Bio-Rad protein assay. Equivalent amounts of protein samples were loaded and separated by SDS/PAGE and transfer-embedded onto a PVDF membrane. The blots were inoculated with antibodies against Nrf2, HO-1 and HIF-1α, Erk (1:600), P-Erk (Thr202/Thr204, 1:600), Akt (1:1000) and P-Akt (Thr308, 1:1000). Afterwards, blocking of the membranes was done in TBS with tween-20 enriched with 5% nonfat dry milk. Thereafter, the membranes were inoculated overnight with HRP-labelled antibodies at RT (room temperature). Detection of blots was done with the ECL detection system and analyzed densitometrically via the Quantity One software (Bio-Rad, Hercules, CA, USA).

### Immunofluorescence staining

To explore Nrf2’s nuclear translocation, fluorescence immunocytochemistry was conducted. GC cells were planted on glass coverslips and were divided into several groups. Fixation of cells (in 4% PFA) was done for 15 minutes at RT and rinsed with cold PBS three times, followed by permeabilization for 10 minutes (in 0.5% Triton X-100). To investigate the cellular localization of Nrf2, cells were probed overnight with the primary antibodies against Nrf2 at 4°C. After rinsing with PBS, cells were inoculated for one hour in Cy3-labelled goat anti-rabbit IgG (secondary antibody) at RT. Nuclei staining was done in 1 μg/ml of DAPI for 5 min in the dark, and then analyzed by a fluorescence microscope (Olympus IX71).

### Statistical analysis

Statistical analyses were implemented by the SPSS v20.0 (Chicago, IL, USA). The chi-squared test was used to determine the association between Nrf2 and HO-1 expression levels and clinicopathological variables. The Spearman's rank-order was adopted to assess the relationship of HO-1 expressions with Nrf2 expression in tissue specimens. Survival plots were performed via the Kaplan-Meier approach, which was then compared with the log-rank test. We adopted the Co’s proportional hazard approach to conduct multivariate analyses for the evaluation of predictive indicators. Data from separate replicate trials were pooled for each treatment, as well as for the control, and the findings were presented as means ± standard error. For normally distributed variables, the Student’s t-test or one-way analysis of variance was used. A p-value of less than 0.05 signified statistical significance.

### Abbreviations

CoCl2: Cobalt dichloride; CIH: chronic intermittent hypoxia; DMEM: Dulbecco's Modified Eagle's Medium; DAB: dianimobenzidine; FBS: Fetal bovine serum; ECL: enhanced chemiluminescence; GRIM-19: gene associated with retinoid-IFN-induced mortality 19; GAPDH: glyceraldehydes-3-phosphate dehydrogenase; HIF-1α: hypoxia-inducible factor-1 alpha; HO-1: heme oxygenase-1; Keap1: Kelch-like ECH-associated protein 1; MMP2: matrix metallopeptidase 2; OSCC: oral squamous cell carcinoma; OGD/R: oxygen-glucose deprivation/reoxygenation; OSC: Oxysophocarpine; PVDF: polyvinylidene fluoride; TME: tumor microenvironment; siRNA: small interfering RNA; VEGFR2: vascular endothelial growth factor receptor; TTB: 2,7,2’,7’-trihydroxy-4,4’7’-trimethoxy-1,1’-Biphenanthrene.

### AUTHOR CONTRIBUTIONS

Ya Yang and Ruitai Fan conceptualized the project and designed the experiments. Ya Yang and Jia Zhang collected data of included patients. Ya Yang performed all the experimental work. Xin Wang participated in data analysis. Hao Gu designed the tables and figures. Junqi Liu offered linguistic assistance for this manuscript. Ya Yang drafted this manuscript, which was reviewed by Ruitai Fan.

### ACKNOWLEDGMENTS

The authors would like to thank the Laboratory of Genetics and Molecular Biology, Medical School, Xi’an Jiaotong University for their technical support.

### CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.
FUNDING

This work was supported by grants from the Medical Science and Technology Co-Construction Project of Henan Province and the National Natural Science Foundation of China (U1504822).

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424. https://doi.org/10.3322/caac.21492 PMID:30207593

2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127:2893–917. https://doi.org/10.1002/ijc.25516 PMID:21351269

3. Zhang XY, Zhang PY. Gastric cancer: somatic genetics as a guide to therapy. J Med Genet. 2017; 54:305–12. https://doi.org/10.1136/jmedgenet-2016-104171 PMID:27609016

4. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66:115–32. https://doi.org/10.3322/caac.21338 PMID:26808342

5. Gao JP, Xu W, Liu WT, Yan M, Zhu ZG. Tumor heterogeneity of gastric cancer: From the perspective of tumor-initiating cell. World J Gastroenterol. 2018; 24:2567–81. https://doi.org/10.3748/wjg.v24.i24.2567 PMID:29962814

6. Zima AA, Cenariu D, Irimie A, Magdo L, Nabavi SM, Atanasov AG, Berindan-Neagoe I. The Role of Nrf2 Activity in Cancer Development and Progression. Cancers (Basel). 2019; 11:1755. https://doi.org/10.3390/cancers11111755 PMID:31717324

7. Panieri E, Buha A, Telkoparan-Akillilar P, Cevik D, Kouretas D, Veskoikis A, Skapera Z, Tsatsakis A, Wallace D, Suzen S, Saso L. Potential Applications of NRF2 Modulators in Cancer Therapy. Antioxidants (Basel). 2020; 9:193. https://doi.org/10.3390/antiox9030193 PMID:32106613

8. Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer. 2012; 12:564–71. https://doi.org/10.1038/nrc3278 PMID:22810811

9. Deshmukh P, Unni S, Krishnappa G, Padmanabhan B. The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2017; 9:41–56. https://doi.org/10.1007/s12551-016-0244-4 PMID:28510041

10. Arneth B. Tumor Microenvironment. Medicina (Kaunas). 2019; 56:15. https://doi.org/10.3390/medicina56010015 PMID:31906017

11. Song WM, Lin X, Liao X, Hu D, Lin J, Sarpel U, Ye Y, Feferman Y, Labow DM, Walsh MJ, Zheng X, Zhang B. Multiscale network analysis reveals molecular mechanisms and key regulators of the tumor microenvironment in gastric cancer. Int J Cancer. 2020; 146:1268–80. https://doi.org/10.1002/ijc.32643 PMID:31463974

12. Yang Y, Li M, Yan Y, Zhang J, Sun K, Qu JK, Wang JS, Duan XY. Expression of RAP1B is associated with poor prognosis and promotes an aggressive phenotype in gastric cancer. Oncol Rep. 2015; 34:2385–94. https://doi.org/10.3892/or.2015.4234 PMID:26329876

13. Kawasaki Y, Ishigami S, Arigami T, Uenosono Y, Yanagita S, Uchikado Y, Kita Y, Nishizono Y, Okumura H, Nakajo A, Kijima Y, Maemura K, Natsugoe S. Clinico-pathological significance of nuclear factor (erythroid-2)-related factor 2 (Nrf2) expression in gastric cancer. BMC Cancer. 2015; 15:5. https://doi.org/10.1186/s12885-015-1008-4 PMID:25588809

14. Yoo NJ, Kim YR, Lee SH. Expression of Nrf2, a cytoprotective protein, in gastric carcinomas. APMIS. 2010; 118:613–4. https://doi.org/10.1111/j.1600-0463.2010.02627.x PMID:20666743

15. Jin M, Wang J, Ji X, Cao H, Zhu J, Chen Y, Yang J, Zhao Z, Ren T, Xing J. MCUR1 facilitates epithelial-mesenchymal transition and metastasis via the mitochondrial calcium dependent ROS/Nrf2/Notch pathway in hepatocellular carcinoma. J Exp Clin Cancer Res. 2019; 38:136. https://doi.org/10.1186/s13046-019-1135-x PMID:30909929

16. Pöloinen P, Jawahar Deen A, Leinonen HM, Jyrkkänen HK, Kuosmanen S, Mononen M, Jain A, Tuomainen T, Pasonen-Seppänen S, Hartikainen JM, Mannermaa A, Nykter M, Tavi P, et al. Nrf2 and SQSTM1/p62 jointly contribute to mesenchymal transition and invasion in glioblastoma. Oncogene. 2019; 38:7473–90. https://doi.org/10.1038/s41388-019-0956-6 PMID:31444413

17. Shi Y, An D, Liu Y, Feng Q, Fang X, Pan G, Wang Q. Propoxur enhances MMP-2 expression and the
corresponding invasion of human breast cancer cells via the ERK/Nrf2 signaling pathway. Oncotarget. 2017; 8:87107–23.  
https://doi.org/10.18632/oncotarget.19081
PMID: 29152067

18. Shen H, Yang Y, Xia S, Rao B, Zhang J, Wang J. Blockage of Nrf2 suppresses the migration and invasion of esophageal squamous cell carcinoma cells in hypoxic microenvironment. Dis Esophagus. 2014; 27:685–92.  
https://doi.org/10.1111/dote.12124
PMID: 24028437

19. Deng Y, Wu Y, Zhao P, Weng W, Ye M, Sun H, Xu M, Wang C. The Nrf2/HO-1 axis can be a prognostic factor in clear cell renal cell carcinoma. Cancer Manag Res. 2019; 11:1221–30.  
https://doi.org/10.2147/CMAR.S188046
PMID: 30799949

20. Lu DY, Yeh WL, Huang SM, Tang CH, Lin HY, Chou SJ. Osteopontin increases heme oxygenase-1 expression and subsequently induces cell migration and invasion in glioma cells. Neuro Oncol. 2012; 14:1367–78.  
https://doi.org/10.1093/neuonc/nos262
PMID: 23074199

21. Liu R, Peng J, Wang H, Li L, Wen X, Tan Y, Zhang L, Wan H, Chen F, Nie X. Oxysophocarpine Retards the Growth and Metastasis of Oral Squamous Cell Carcinoma by Targeting the Nrf2/HO-1 Axis. Cell Physiol Biochem. 2018; 49:1717–33.  
https://doi.org/10.1056/1159/000493615
PMID: 30231242

22. Cernigliaro C, D’Anneo A, Carlisi D, Giuliano M, Marino Gammazza A, Barone R, Longhitano L, Cappello F, Emanuele S, Distefano A, Campanella C, Calvaruso G, Lauricella M. Ethanol-Mediated Stress Promotes Autophagic Survival and Aggressiveness of Colon Cancer Cells via Activation of Nrf2/HO-1 Pathway. Cancers (Basel). 2019; 11:505.  
https://doi.org/10.3390/cancers11040505
PMID: 30974805

23. Wang X, Ye T, Xue B, Yang M, Li R, Xu X, Zeng X, Tian N, Bao L, Huang Y. Mitochondrial GRIM-19 deficiency facilitates gastric cancer metastasis through oncogenic ROS-NRF2-HO-1 axis via a NRF2-HO-1 loop. Gastric Cancer. 2021; 24:117–32.  
https://doi.org/10.1007/s10120-020-01111-2
PMID: 32770429

24. Zhang HS, Zhang ZG, Du GY, Sun HL, Liu HY, Zhou Z, Gou XM, Wu XH, Yu XY, Huang YH. Nrf2 promotes breast cancer cell migration via up-regulation of G6PD/HIF-1α/Notch1 axis. J Cell Mol Med. 2019; 23:3451–63.  
https://doi.org/10.1111/jcmm.14241
PMID: 30809937

25. Kang HS, Kwon HY, Kim IK, Ban WH, Kim SW, Kang HH, Yeo CD, Lee SH. Intermittent hypoxia exacerbates tumor progression in a mouse model of lung cancer. Sci Rep. 2020; 10:1854.  
https://doi.org/10.1038/s41598-020-58906-7
PMID: 32024881

26. Liu L, Zhao Z, Yin Q, Zhang X. TTB Protects Astrocytes Against Oxygen-Glucose Deprivation/Reoxygenation-Induced Injury via Activation of Nrf2/HO-1 Signaling Pathway. Front Pharmacol. 2019; 10:792.  
https://doi.org/10.3389/fphar.2019.00792
PMID: 31379570

27. Shah S, Brock EJ, Ji K, Mattingly RR. Ras and Rap1: A tale of two GTPases. Semin Cancer Biol. 2019; 54:29–39.  
https://doi.org/10.1016/j.semcancer.2018.03.005
PMID: 29621614

28. Zhu J, Wang Y, Hu Q, Yuan R, Ye J. Rottlerin acts as a therapeutic in primary open-angle glaucoma by targeting the trabecular meshwork via activation of Rap1 signaling. Pharmacol Res. 2020; 159:104780.  
https://doi.org/10.1016/j.phrs.2020.104780
PMID: 32360586

29. Liu M, Wang Y, Lu H, Wang H, Shi X, Shao X, Li YX, Zhao Y, Wang YL. mir-518b Enhances Human Trophoblast Cell Proliferation Through Targeting Rap1b and Activating Ras-MAPK Signal. Front Endocrinol (Lausanne). 2018; 9:100.  
https://doi.org/10.3389/fendo.2018.00100
PMID: 29599749

30. Ma XL, Shen MN, Hu B, Wang BL, Yang WJ, Lv LH, Wang H, Zhou Y, Jin AL, Sun YF, Zhang CY, Qiu SJ, Pan BS, et al. CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis. J Hematol Oncol. 2019; 12:37.  
https://doi.org/10.1186/s13045-019-0724-7
PMID: 30971294

31. Jasek-Gajda E, Jurkowski H, Jasińska M, Lis GJ. Targeting the MAPK/ERK and PI3K/AKT Signaling Pathways Affects NRF2, Trx and GSH Antioxidant Systems in Leukemia Cells. Antioxidants (Basel). 2020; 9:633.  
https://doi.org/10.3390/antiox9070633
PMID: 32709140

32. Yang Y, Tian Z, Guo R, Ren F. Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways. Oxid Med Cell Longev. 2020; 2020:9867595.  
https://doi.org/10.1155/2020/9867595
PMID: 32765809

www.aging-us.com 3311 AGING
33. Shafei MA, Forshaw T, Davis J, Flemban A, Qualtrough D, Dean S, Perks C, Dong M, Newman R, Conway ME. BCATc modulates crosstalk between the PI3K/Akt and the Ras/ERK pathway regulating proliferation in triple negative breast cancer. Oncotarget. 2020; 11:1971–87. https://doi.org/10.18632/oncotarget.27607 PMID:32523652

34. Lian L, Li XL, Xu MD, Li XM, Wu MY, Zhang Y, Tao M, Li W, Shen XM, Zhou C, Jiang M. VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer. BMC Cancer. 2019; 19:183. https://doi.org/10.1186/s12885-019-5322-0 PMID:30819137

35. Peng W, Zhang F, Wang Z, Li D, He Y, Ning Z, Sheng L, Wang J, Xia X, Yu C, Wang Z, Zhao Y, Liang H, et al. Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China. Cancer Manag Res. 2020; 12:6977–85. https://doi.org/10.2147/CMAR.S249153 PMID:32821164

36. Arnold D, Fuchs CS, Tabernero J, Ohtsu A, Zhu AX, Garon EB, Mackey JR, Paz-Ares L, Baron AD, Okusaka T, Yoshino T, Yoon HH, Das M, et al. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann Oncol. 2017; 28:2932–42. https://doi.org/10.1093/annonc/mdx514 PMID:28950290